Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 187 matching trials from the live ClinicalTrials.gov search.
Conditions
Dermatomyositis
Interventions
PF-06823859 low, Placebo Arm, PF-06823859 high
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 17 more
Conditions
SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
Interventions
CTX112
Biological
Lead sponsor
CRISPR Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
La Jolla, California • Redwood City, California • Chicago, Illinois + 6 more
Recruiting No phase listed Observational

IL1 Inhibition in FOP

NCT06724562
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Anti-IL1 Therapy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Inclusion Body Myositis
Interventions
Adipose Derived Regenerative Cells
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
MYOPATHY
Interventions
Hematopoietic stem cell transplantation, Cyclophosphamide, Mesna, ATG(rabbit), Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Dermatomyositis
Interventions
Octagam 10%, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years to 79 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Huntington Beach, California • Los Angeles, California • Orange, California + 14 more
Conditions
Dermatomyositis, Dermatomyositis, Adult Type
Interventions
Brepocitinib
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases
Interventions
Stem Cell Transplantation, CD34 selection
Procedure · Device
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
Interventions
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
6 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
31
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 22 more
Conditions
Rheumatic Diseases, Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Not listed
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
Up to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Completed Phase 4 Interventional Results available

Myositis Interstitial Lung Disease Nintedanib Trial

NCT05799755
Conditions
Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions
Nintedanib, Placebo, Standard of Care
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Conditions
Systemic Lupus Erythematosus
Interventions
Sifalimumab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
24
States / cities
Anniston, Alabama • Scottsdale, Arizona • San Leandro, California + 21 more
Conditions
Dermatomyositis
Interventions
Baricitinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Completed No phase listed Observational Accepts healthy volunteers

Study and Treatment of Inflammatory Muscle Diseases

NCT00001265
Conditions
Dermatomyositis, Polymyositis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
16 Years and older
Enrollment
1,325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
Interventions
Pozelimab/Cemdisiran
Combination Product
Lead sponsor
Austin Neuromuscular Center
Other
Eligibility
45 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Austin, Texas
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Interventions
FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo
Dietary Supplement
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis

NCT07823101
Conditions
IBM, Inclusion Body Myositis, Myopathy, Myositis, ALS (Amyotrophic Lateral Sclerosis), PLS
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Dermatomyositis
Interventions
Prednisone, Methotrexate, Etanercept
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene, Placebo
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 2Phase 3 Interventional Results available

Belimumab in Idiopathic Inflammatory Myositis

NCT02347891
Conditions
Myositis
Interventions
Belimumab, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Great Neck, New York